StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$435.64−3.18 (-0.72%)

Close on Nov 20, 2026Market cap $235.52BP/E 25.3Yield 2.22%

Amgen gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Amgen's gross profit for the twelve months ending Sep 30, 2026 was $27.58B, up 15.9% year over year. For fiscal 2025 it was $24.71B, up 20.2% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $24.71B in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$24.71B+20.2%
FY2024Dec 31, 2024$20.57B+4.2%
FY2023Dec 31, 2023$19.74B-0.9%
FY2022Dec 31, 2022$19.92B+2.0%
FY2021Dec 31, 2021$19.53B+1.3%
FY2020Dec 31, 2020$19.27B+1.4%
FY2019Dec 31, 2019$19.01B-3.3%
FY2018Dec 31, 2018$19.65B+4.6%
FY2017Dec 31, 2017$18.78B-0.3%
FY2016Dec 31, 2016$18.83B+8.0%
FY2015Dec 31, 2015$17.44B+11.5%
FY2014Dec 31, 2014$15.64B+2.0%
FY2013Dec 31, 2013$15.33B+9.0%
FY2012Dec 31, 2012$14.07B+9.3%
FY2011Dec 31, 2011$12.87B–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$7.58B+17.0%
Q2 FY2026Jun 30, 2026$7.24B+17.4%
Q1 FY2026Mar 31, 2026$5.87B+13.4%
Q4 FY2025Dec 31, 2025$6.89B+15.3%
Q3 FY2025Sep 30, 2025$6.48B+24.7%
Q2 FY2025Jun 30, 2025$6.17B+19.7%
Q1 FY2025Mar 31, 2025$5.18B+22.0%
Q4 FY2024Dec 31, 2024$5.97B+17.5%
Q3 FY2024Sep 30, 2024$5.19B+1.9%
Q2 FY2024Jun 30, 2024$5.15B-0.4%
Q1 FY2024Mar 31, 2024$4.25B-3.1%
Q4 FY2023Dec 31, 2023$5.08B-0.2%
Q3 FY2023Sep 30, 2023$5.10B+0.7%
Q2 FY2023Jun 30, 2023$5.17B+1.8%
Q1 FY2023Mar 31, 2023$4.39B-6.2%
Q4 FY2022Dec 31, 2022$5.09B-0.7%
Q3 FY2022Sep 30, 2022$5.06B+14.8%
Q2 FY2022Jun 30, 2022$5.08B+7.3%
Q1 FY2022Mar 31, 2022$4.68B+2.9%
Q4 FY2021Dec 31, 2021$5.13B+16.0%
Q1 FY2021Mar 31, 2021$4.41B+0.7%
Q4 FY2020Dec 31, 2020$4.74B+3.8%
Q3 FY2020Sep 30, 2020$4.54B+7.4%
Q2 FY2020Jun 30, 2020$4.42B-9.9%
Q1 FY2020Mar 31, 2020$4.38B-2.1%
Q2 FY2019Jun 30, 2019$4.56B-2.0%
Q1 FY2019Mar 31, 2019$4.23B-3.8%
Q4 FY2018Dec 31, 2018$4.91B+8.8%
Q3 FY2018Sep 30, 2018$4.47B+0.2%
Q2 FY2018Jun 30, 2018$4.66B+2.3%
Q1 FY2018Mar 31, 2018$4.40B+4.7%
Q4 FY2017Dec 31, 2017$4.51B-1.9%
Q3 FY2017Sep 30, 2017$4.46B-0.6%
Q2 FY2017Jun 30, 2017$4.55B+2.8%
Q1 FY2017Mar 31, 2017$4.20B–
Q4 FY2016Dec 31, 2016$4.60B–
Q3 FY2016Sep 30, 2016$4.49B–
Q2 FY2016Jun 30, 2016$4.42B–

More Amgen figures

See a number that looks wrong?